Kurs
-34,94%
Likviditet
7,39 MSEK
Kalender
| Tid* | ||
| 2025-05-20 | N/A | Årsstämma |
| 2025-05-20 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-25 | 08:00 | Bokslutskommuniké 2024 |
| 2024-12-17 | - | Extra Bolagsstämma 2024 |
| 2024-11-19 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-27 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2024-05-21 | - | Årsstämma |
| 2024-05-21 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-20 | - | Bokslutskommuniké 2023 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-24 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2023-05-23 | - | Årsstämma |
| 2023-05-23 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-11 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2022-05-10 | - | Årsstämma |
| 2022-05-10 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-29 | - | Extra Bolagsstämma 2022 |
| 2022-02-22 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-13 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-20 | - | Split SYNT 1:10 |
| 2021-05-12 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-02 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
| 2020-07-14 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-05 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-12 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-14 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-30 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
| 2019-04-29 | - | Årsstämma |
| 2019-04-29 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2018-04-25 | - | Årsstämma |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-21 | - | Bokslutskommuniké 2017 |
| 2017-11-10 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2017-04-25 | - | Årsstämma |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-10-28 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-26 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-27 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2016-04-26 | - | Årsstämma |
| 2016-04-26 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-10-30 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-13 | - | Årsstämma |
| 2015-04-13 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-17 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2015-02-13 | - | Bokslutskommuniké 2014 |
| 2014-11-28 | - | Kvartalsrapport 2014-Q3 |
| 2014-09-26 | - | Extra Bolagsstämma 2014 |
| 2014-08-29 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The costs for the second quarter are expected to be on a par with the same period last year, which therefore also applies to the entire first half of 2024. This outcome is the result of good cost control and efficiency improvements in operations globally. All figures are preliminary and unaudited. The full interim report for the second quarter will be published on August 27, 2024, as previously announced.
"We know from experience that our business sometimes has large fluctuations over the quarters. After four straight quarters of record sales, we have now been negatively affected by unforeseen events in the organization. This has led to a number of sales processes being hampered. The situation is isolated to the subsidiary in the USA. Other priority regions continue to develop well. Positive in this context is also that the response from the market in North America as well as globally for our offer is undiminished strong," says Ulrik Harrysson, CEO, SyntheticMR.
This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-07-2024 21:34 CET.
For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com